Back to Search
Start Over
THE SUSTAINED OCS-SPARING EFFECT OF MEPOLIZUMAB: RESULTS FROM THE REAL-WORLD REALITI-A STUDY AT 2 YEARS
- Source :
- Annals of Allergy, Asthma & Immunology; November 2022, Vol. 129 Issue: 5, Number 5 Supplement 1 pS43-S43, 1p
- Publication Year :
- 2022
-
Abstract
- A main goal of asthma treatment is to reduce or eliminate oral corticosteroid (OCS) use due to their adverse effects. Clinical and real-world studies have reported mepolizumab reduces OCS use in patients with severe eosinophilic asthma (SEA); further evidence of the longer-term OCS-sparing effect of mepolizumab is needed.
Details
- Language :
- English
- ISSN :
- 10811206
- Volume :
- 129
- Issue :
- 5, Number 5 Supplement 1
- Database :
- Supplemental Index
- Journal :
- Annals of Allergy, Asthma & Immunology
- Publication Type :
- Periodical
- Accession number :
- ejs61918968
- Full Text :
- https://doi.org/10.1016/j.anai.2022.08.625